TearScience 診斷/治療 Meibomian Gland Dysfunction (瞼板腺功能障礙)(乾眼症)

TearScience Makes Its Dry Eye Technology More Accessible to Premium Surgical Practices

FROM TEARSCIENCE INC. — 4/23/2014 TearScience announced that it will make the LipiView Interferometer and LipiFlow Thermal Pulsation System available for individual purchase, allowing premium surgical practices to implement the innovative technology with the flexibility best suited to their individual operational strategy, according to a company news release. TearScience technology greatly improves a surgically-focused eye care practice's ability to identify, diagnose, and treat the root of Meibomian Gland Dysfunction (MGD), the leading cause of dry eye."TearScience is making its dry eye technology available to eye care professionals interested in dramatically changing the way MGD is managed," Wade Hampton, chief commercial officer of TearScience, said in the news release. "The LipiView Ocular Surface Interferometer, the Korb Meibomian Gland
 Evaluator (MGE), and the LipiFlow Thermal Pulsation System can now be purchased as a system or separately, to significantly reduce the barrier for acquiring and implementing a widely adopted, proven, and efficacious dry eye solution."

Dry Eye Patients Highly Recommend LipiFlow
In a recent survey conducted with 465 dry eye patients located in 49 states throughout the U.S., 82% of patients treated with LipiFlow would recommend the treatment to family and 
friends. Among the remaining 18% of patients treated with LipiFlow, 15% noted that it was too early to tell if they would recommend it or not."LipiFlow is a breakthrough treatment specific for MGD," John Sheppard, MD, MMSc, president of Virginia Eye Consultants in Norfolk, Virginia, said in the news release. "In our office, we have achieved a high satisfaction rating from 92% of our LipiFlow patients over the last 10 months. We regard our LipiFlow patients as premium line, with dedicated counselors, information, schedules, hot lines, and service. Elevating the level of care we provide for ocular surface comfort has raised overall patient satisfaction and outcome confidence across all of our entire premium offerings." To date, nearly 40,000 LipiFlow treatments have been performed to treat the leading cause of dry eye. The TearScience Dry Eye Solution is now being used commercially at more than 250 eye care practices and academic institutions worldwide.

TearScience Showcases Its Technology at ASCRS 2014
Physicians can visit TearScience at exhibit booth #463 at the American Society of Cataract and Refractive Surgery's (ASCRS) annual meeting in Boston from April 26-29, 2014. TearScience will offer live LipiFlow patient case reports, complimentary LipiView tear film lipid layer
 evaluations, physician presentations, treatment experiences, and special promotional pricing. For full details, visit TearScience's ASCRS events web page.